Muscle proteins in plasma associate to distinguished phenotypes in amyotrophic lateral sclerosis
Preprint
Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by death of upper and lower motor neurons, usually presented with clinical heterogeneity. Fluid biomarker development remains dominated by neurofilament light chain (NEFL), a marker of neuroaxonal injury. NEFL is however unspecific to ALS and its phenotypes and there is currently a lack of biomarkers that capture ALS heterogeneity such as onset site and ALS-frontotemporal spectrum disorder (ALS-FTSD). Therefore, we investigated whether plasma proteomics could reveal pathway-level signatures that stratify and explain ALS heterogeneity. Methods: We profiled ∼5,400 plasma proteins (Olink Explore HT) in 299 patients with ALS and 50 age- and sex comparable healthy controls. We used two complementary analytic frameworks: (i) differential protein abundance analysis to identify altered proteins in ALS and across clinical subgroups, and (ii) weighted gene correlation network analysis (WGCNA) to identify coordinated protein modules and relate them to ALS diagnosis and to ALS-specific clinical traits (site of onset, ALS-FTSD, ALS functional rating scale-revised (ALSFRS-R) score, and plasma NEFL). Results: Differential abundance analysis identified 56 proteins altered in ALS versus controls, of which 40 were increased. WGCNA identified 11 co-expression modules, with ALS samples having the strongest correlation to a protein module (n=51) highly enriched for muscle-related proteins. Out of the 40 proteins that had increased expression levels, 29 overlapped with the muscle-enriched protein module, indicating that muscle related proteins are the dominant circulating proteomic signature in ALS. This signal extended to clinical stratification: spinal-onset patients showed a strong positive association with the muscle-module. Further, differential abundance analysis of spinal- versus bulbar-onset ALS identified changes that mapped predominantly to the same module, supporting a molecular signature of onset phenotype. In contrast, cognitive status (ALS-FTSD) mapped to distinct modules enriched for extracellular matrix/cell-adhesion pathways, consistent with a separable biological axis of disease heterogeneity. Although multiple modules correlated with NEFL, trait-specific signatures were not fully explained by neuroaxonal injury. Notably, the muscle-enriched module increased with higher NEFL and lower ALSFRS-R, supporting its interpretation as a severity-linked, muscle-involvement proxy. Conclusions: Large-scale plasma proteomics reveals that heterogeneity in ALS reflects underlying biological structures. We identified a dominant muscle-associated protein network that distinguished ALS patients from controls and correlated with disease onset phenotype and severity, alongside distinct protein networks linked to ALS-FTSD. By integrating differential protein abundance with network-based analysis, we defined pathway-level biomarker signatures that extend beyond NEFL, enabling biologically informed patient stratification and improved therapeutic monitoring.Keywords
Funding Information
- Börje Salming foundation
- Region Stockholm
- ALS-fonden
This publication has 36 references indexed in Scilit:
- Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large‐Scale, Multi‐Cohort Proteomic StudyAnnals of Neurology, 2025
- Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen‐Treated ALSMuscle & Nerve, 2025
- Lifestyle and medical conditions in relation to ALS risk and progression—an introduction to the Swedish ALSrisc StudyJournal of Neurology, 2024
- Repeated cognitive assessments show stable function over time in patients with ALSJournal of Neurology, 2024
- Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosisJournal of the Neurological Sciences, 2020
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in NeurologyJAMA Neurology, 2019
- Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversionAnnals of Neurology, 2018
- Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patientsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2014
- Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein HomeostasisNeuron, 2013
- Stages of pTDP‐43 pathology in amyotrophic lateral sclerosisAnnals of Neurology, 2013